Functional matrix metalloproteinase (MMP)-9 genetic variants modify the effects of hemodialysis on circulating MMP-9 levels

Clinica Chimica Acta

Volumn 414, Issue , 2012, Pages 46-51

  Marson, Bernardo P ^a   Lacchini, Riccardo ^a   Belo, Vanessa ^b   Mattos, Silvia G ^c   da Costa, Bartira P ^c   Poli de Figueiredo, Carlos E ^c   Tanus Santos, Jose E ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

End stage kidney disease; Haplotypes; Hemodialysis; Matrix metalloproteinase 9; Polymorphism

Indexed keywords

GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TIMP1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BIOASSAY; DNA POLYMORPHISM; END STAGE RENAL DISEASE; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MMP 9 GENE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TAQMAN ALLELE DISCRIMINATION ASSAY; TREATMENT DURATION; TREATMENT RESPONSE; ADOLESCENT; BLOOD; CHRONIC KIDNEY FAILURE; GENETICS; MIDDLE AGED; RENAL REPLACEMENT THERAPY;

ADOLESCENT; ADULT; AGED; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; RENAL DIALYSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; YOUNG ADULT;

EID: 84865817719     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.08.014     Document Type: Article

References (35)

1. Stenvinkel, P., Pecoits-Filho, R., Lindholm, B., Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem. J Am Soc Nephrol 14 (2003), 1927–1939.
2. Mizobuchi, M., Towler, D., Slatopolsky, E., Vascular calcification: the killer of patients with chronic kidney disease. J Am Soc Nephrol 20 (2009), 1453–1464.
3. Pai, A., Leaf, E.M., El-Abbadi, M., Giachelli, C.M., Elastin degradation and vascular smooth muscle cell phenotype change precede cell loss and arterial medial calcification in a uremic mouse model of chronic kidney disease. Am J Pathol 178 (2011), 764–773.
4. Marson, B.P., de Figueiredo, C.E., Tanus-Santos, J.E., Imbalanced matrix metalloproteinases in cardiovascular complications of end-stage kidney disease: a potential pharmacological target. Basic Clin Pharmacol Toxicol 110 (2012), 409–415.
5. Fontana, V., Silva, P.S., Gerlach, R.F., Tanus-Santos, J.E., Circulating matrix metalloproteinases and their inhibitors in hypertension. Clin Chim Acta 413 (2012), 656–662.
6. Van den Steen, P.E., Dubois, B., Nelissen, I., Rudd, P.M., Dwek, R.A., Opdenakker, G., Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol 37 (2002), 375–536.
7. Chung, A.W., Yang, H.H., Sigrist, M.K., et al. Matrix metalloproteinase-2 and -9 exacerbate arterial stiffening and angiogenesis in diabetes and chronic kidney disease. Cardiovasc Res 84 (2009), 494–504.
8. Addabbo, F., Mallamaci, F., Leonardis, D., et al. Searching for biomarker patterns characterizing carotid atherosclerotic burden in patients with reduced renal function. Nephrol Dial Transplant 22 (2007), 3521–3526.
9. Chen, N.X., O'Neill, K.D., Chen, X., Kiattisunthorn, K., Gattone, V.H., Moe, S.M., Activation of arterial matrix metalloproteinases leads to vascular calcification in chronic kidney disease. Am J Nephrol 34 (2011), 211–219.
10. Ebihara, I., Nakamura, T., Tomino, Y., Shimada, N., Koide, H., Metalloproteinase-9 mRNA expression in monocytes from patients with chronic renal failure. Am J Nephrol 18 (1998), 305–310.
11. Pawlak, K., Mysliwiec, M., Pawlak, D., Peripheral blood level alterations of MMP-2 and MMP-9 in patients with chronic kidney disease on conservative treatment and on hemodialysis. Clin Biochem 44 (2011), 838–843.
12. Rysz, J., Banach, M., Stolarek, R.A., et al. Serum metalloproteinases MMP-2, MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in patients on hemodialysis. Int Urol Nephrol 43 (2011), 491–498.
13. Chou, F.P., Chu, S.C., Cheng, M.C., et al. Effect of hemodialysis on the plasma level of type IV collagenases and their inhibitors. Clin Biochem 35 (2002), 383–388.
14. Pawlak, K., Pawlak, D., Mysliwiec, M., Circulating beta-chemokines and matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system in hemodialyzed patients—role of oxidative stress. Cytokine 31 (2005), 18–24.
15. Friese, R.S., Rao, F., Khandrika, S., et al. Matrix metalloproteinases: discrete elevations in essential hypertension and hypertensive end-stage renal disease. Clin Exp Hypertens 31 (2009), 521–533.
16. Polañska, B., Makulska, I., Augustyniak, D., Niemczuk, M., Zwoliñska, D., Jankowski, A., Serum levels of MMP-9 in children and young adults with chronic kidney disease treated conservatively and undergoing hemodialysis. Cent Eur J Immunol 32 (2007), 66–71.
17. Musial, K., Zwolinska, D., Matrix metalloproteinases and soluble Fas/FasL system as novel regulators of apoptosis in children and young adults on chronic dialysis. Apoptosis 16 (2011), 653–659.
18. Zhang, B., Ye, S., Herrmann, S.M., et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 99 (1999), 1788–1794.
19. Metzger, I.F., Luizon, M.R., Lacchini, R., Tanus-Santos, J.E., Genetic variants in matrix metalloproteinase-9 gene modify metalloproteinase-9 levels in black subjects. DNA Cell Biol 31 (2012), 504–510.
20. Lacchini, R., Jacob-Ferreira, A.L., Luizon, M.R., et al. Matrix metalloproteinase 9 gene haplotypes affect left ventricular hypertrophy in hypertensive patients. Clin Chim Acta 411 (2010), 1940–1944.
21. Medley, T.L., Cole, T.J., Dart, A.M., Gatzka, C.D., Kingwell, B.A., Matrix metalloproteinase-9 genotype influences large artery stiffness through effects on aortic gene and protein expression. Arterioscler Thromb Vasc Biol 24 (2004), 1479–1484.
22. Blankenberg, S., Rupprecht, H.J., Poirier, O., et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 107 (2003), 1579–1585.
23. Palei AC, Sandrim VC, Amaral LM, et al. Matrix metalloproteinase-9 polymorphisms affect plasma MMP-9 levels and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy. Pharmacogenomics J in press, http://dx.doi.org/10.1038/tpj.2011.31.
24. Belo, V.A., Souza-Costa, D.C., Luizon, M.R., et al. Matrix metalloproteinase-9 genetic variations affect MMP-9 levels in obese children. Int J Obes (Lond) 36 (2012), 69–75.
25. Marson, B.P., Lacchini, R., Belo, V., et al. Matrix metalloproteinase (MMP)-2 genetic variants modify the circulating MMP-2 levels in end-stage kidney disease. Am J Nephrol 35 (2012), 209–215.
26. Hirakawa, S., Lange, E.M., Colicigno, C.J., Freedman, B.I., Rich, S.S., Bowden, D.W., Evaluation of genetic variation and association in the matrix metalloproteinase 9 (MMP9) gene in ESRD patients. Am J Kidney Dis 42 (2003), 133–142.
27. Demacq, C., de Souza, A.P., Machado, A.A., Gerlach, R.F., Tanus-Santos, J.E., Genetic polymorphism of matrix metalloproteinase (MMP)-9 does not affect plasma MMP-9 activity in healthy subjects. Clin Chim Acta 365 (2006), 183–187.
28. Demacq, C., Vasconcellos, V.B., Marcaccini, A.M., Gerlach, R.F., Silva, W.A. Jr., Tanus-Santos, J.E., Functional polymorphisms in the promoter of the matrix metalloproteinase-9 (MMP-9) gene are not linked with significant plasma MMP-9 variations in healthy subjects. Clin Chem Lab Med 46 (2008), 57–63.
29. Bouvet, C., Moreau, S., Blanchette, J., de Blois, D., Moreau, P., Sequential activation of matrix metalloproteinase 9 and transforming growth factor beta in arterial elastocalcinosis. Arterioscler Thromb Vasc Biol 28 (2008), 856–862.
30. Souza-Tarla, C.D., Uzuelli, J.A., Machado, A.A., Gerlach, R.F., Tanus-Santos, J.E., Methodological issues affecting the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Clin Biochem 38 (2005), 410–414.
31. Gerlach, R.F., Uzuelli, J.A., Souza-Tarla, C.D., Tanus-Santos, J.E., Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Anal Biochem 344 (2005), 147–149.
32. Shimajiri, S., Arima, N., Tanimoto, A., et al. Shortened microsatellite d(CA)21 sequence down-regulates promoter activity of matrix metalloproteinase 9 gene. FEBS Lett 455 (1999), 70–74.
33. Zhang, B., Henney, A., Eriksson, P., Hamsten, A., Watkins, H., Ye, S., Genetic variation at the matrix metalloproteinase-9 locus on chromosome 20q12.2–13.1. Hum Genet 105 (1999), 418–423.
34. Castro, M.M., Rizzi, E., Ceron, C.S., et al. Doxycycline ameliorates 2K-1C hypertension-induced vascular dysfunction in rats by attenuating oxidative stress and improving nitric oxide bioavailability. Nitric Oxide 26 (2012), 162–168.
35. Castro, M.M., Tanus-Santos, J.E., Gerlach, R.F., Matrix metalloproteinases: targets for doxycycline to prevent the vascular alterations of hypertension. Pharmacol Res 64 (2011), 567–572.